DHMC-led study finds common OTC drug results in less bleeding, but not always as effective, as prescription blood thinners in preventing blood clots after total hip, knee replacement

Vincent D. Pellegrini, MD

[S]urgeons and physicians have long debated the value of...aspirin compared with traditional anticoagulants when trying to balance the risks of excessive bleeding with the benefits of thinning the blood to avoid blood clots—and both may be right

Vincent D. Pellegrini, MD

A study based at Dartmouth Health’s Dartmouth Hitchcock Medical Center (DHMC) found that over-the-counter aspirin often results in less bleeding and can be as effective at preventing dangerous blood clots in knee replacement but not hip replacement patients when compared to prescription blood-thinners. The findings of the Comparative Effectiveness of Pulmonary Embolism Prevention After Hip and Knee Replacement (PEPPER) trial, which spanned 10 years and involved nearly 19,000 participants, were published in the New England Journal of Medicine.

Venous thromboembolism (VTE), which may present as pulmonary embolism (PE) or deep vein thrombosis, poses a potentially life-threatening risk for patients who undergo total replacement of the knee or hip. This results from bone marrow fat being disturbed when the prosthetic device is placed during surgery.

Preventative medications after surgery are recommended to prevent VTE; however, they may increase the risk of serious bleeding and wound complications. Orthopaedic surgeons frequently recommend aspirin both for its minimal bleeding risk and low cost, but available evidence was previously lacking to confirm its effectiveness at VTE prevention compared to prescription anticoagulants.

Led by principal investigator Vincent D. Pellegrini Jr., MD, professor emeritus of orthopaedics and health practice/clinical policy at the Geisel School of Medicine at Dartmouth, the PEPPER trial studied the effectiveness of aspirin in preventing blood clots in knee- and hip-replacement patients compared with rivaroxaban and warfarin, commonly known by the brand names Xarelto and Coumadin, respectively. Among 18,883 participants at 34 sites across the United States and Canada, patients were randomly assigned aspirin, warfarin or rivaroxaban. 

Of the patients prescribed aspirin, 1.26% experienced a primary effectiveness outcome event, like blood clots or death, within six months of surgery. In the warfarin group, primary effectiveness outcome events were observed in 1.23% of participants, and in 0.94% of the rivaroxaban group. Based on these numbers, aspirin was considered to be not as effective as rivaroxaban in preventing pulmonary embolism and death. At the same time, bleeding risk with aspirin was less than with either warfarin or rivaroxaban.

“Despite widespread agreement that some blood thinning is desirable after joint replacement, surgeons and physicians have long debated the value of a simple baby aspirin compared with traditional anticoagulants when trying to balance the risks of excessive bleeding with the benefits of thinning the blood to avoid blood clots—and both may be right,” Pellegrini said. “The PEPPER trial is the largest study conducted on this subject and has revealed situations where aspirin is safer (because of less bleeding risk) and appears no less effective than blood thinners in preventing PE, such as after total knee replacement, while also identifying other situations where blood thinners appear to have greater effectiveness in preventing PE, particularly after total hip replacement.”

Researchers at the University of Maryland played a critical role in the trial, facilitating its data coordinating center.

“By directly comparing three widely used approaches in thousands of patients, the PEPPER trial provides important evidence to help patients and their care teams make more informed decisions,” said Jay S. Magaziner, PhD, MSH, professor of epidemiology and public health at the University of Maryland School of Medicine and director at UMaryland’s Center for Research on Aging, who assisted Pellegrini in developing the trial.

To read the full study, visit go.d-h.org/smnyrj.

About Dartmouth Health

Dartmouth Health, New Hampshire’s only academic health system and largest private employer, serves patients across New England. Dartmouth Health provides access to more than 2,300 providers in nearly every area of medicine, delivering care at its flagship hospital, Dartmouth Hitchcock Medical Center (DHMC) in Lebanon, NH. Its network of hospitals, outpatient centers, clinics and home care facilities, spans a broad geographical area. Year after year, DHMC is named the #1 hospital in New Hampshire by U.S. News & World Report, and is consistently recognized for high performance in numerous clinical specialties and procedures. Dartmouth Health includes Dartmouth Cancer Center, northern New England’s only National Cancer Institute-designated Comprehensive Cancer Centers and one of less than than 60 total nationally; Dartmouth Health Children’s, which includes the state’s only children’s hospital, the Golisano Children's Hospital at Dartmouth Health, and more than 20 locations around the region; eight member hospitals in Lebanon, Keene, Claremont, Hampstead, and New London, NH, and Windsor and Bennington, VT; Dartmouth Health Home Care; Dartmouth Health Connected Care Center for Telehealth, serving patients as far away as Texas; and more than 30 primary and multi-specialty clinics across New Hampshire and Vermont. Through its partnership with Dartmouth College, Dartmouth’s Geisel School of Medicine and the White River Junction VA Medical Center, Dartmouth Health trains nearly 400 medical residents and fellows annually and performs cutting-edge research and clinical trials with international impact. Dartmouth Health and its more than 16,000 employees are committed to serving the healthcare needs of everyone in the communities it serves and to providing every patient with exceptional, state-of-the-art, personalized care. Learn more at dartmouth-health.org.